SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer (Pancreas)
A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
Sponsor: Chang Gung Memorial Hospital
Listed as NCT03443492, this PHASE2 trial focuses on Locally Advanced or Metastatic Pancreatic Cancer and remains completed. Sponsored by Chang Gung Memorial Hospital, it has been updated 9 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Mar 2025 — Jan 2026 [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Sep 2024 — Mar 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Enrolling By Invitation → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2018 — Sep 2019 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chang Gung Memorial Hospital
- China Medical University Hospital
- E-DA Hospital
- Kaohsiung Medical University
- National Cheng-Kung University Hospital
- National Health Research Institutes, Taiwan
- National Taiwan University Hospital
- Taipei Medical University Shuang Ho Hospital
- Taipei Veterans General Hospital, Taiwan
- Tri-Service General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .